Answer first
The operating thesis is unchanged. Risk-adjusted product and pipeline SOTP replaces adjusted EPS times P/E. It exposes wider debt-sensitive patent and pipeline tails. The decision moves from starter long to pass and watch.
Original targets were $17.85, $27.50, and $39.65. Revised targets are $5.68, $25.53, and $52.55. Weighted value changes from $28.1250 to $27.3260.
Risk-adjusted product and pipeline SOTP
On narrow screens, swipe the table horizontally to view every scenario field.
| Case | Probability | Year 1 FCF | Year 5 FCF | Pipeline rNPV | Net debt | Target |
|---|---|---|---|---|---|---|
| Bear | 25% | $9.5B | $7.5B | $7.0B | $56.0B | $5.68 |
| Base | 50% | $11.8B | $12.0B | $20.0B | $48.0B | $25.53 |
| Bull | 25% | $12.5B | $17.0B | $35.0B | $40.0B | $52.55 |
Approved commercial cash flow is valued by enterprise FCF DCF. Incremental unapproved pipeline rNPV is added separately. Cross-checks are not averaged.
Five-pillar reassessment
| Pillar | Prior | Revised | Rule |
|---|---|---|---|
| Business Quality | 4.5 | 4.5 | Unchanged |
| Management Quality | 5.0 | 5.0 | Unchanged |
| Industry Tailwind | 6.5 | 6.5 | Unchanged |
| Valuation and Margin of Safety | 7.0 | 6.0 | R1 band change |
| Risk and Asymmetry | 5.0 | 3.5 | R2 bear target |
| Conviction | 5.675 | 5.225 | Pass band |
Why this method fits
Pfizer combines a mature commercial portfolio, normalized COVID cash, concentrated losses of exclusivity, Seagen integration, uncertain pipeline probabilities, elevated debt, and a large dividend. The selected method makes each value bridge explicit.
Normalized FCF DCF is the commercial engine. Normalized EPS and EV to EBITDA are secondary checks. No incompatible outputs are averaged.
Frozen evidence
Reference price, cutoff, filings, financial facts, operating evidence, and source register remain frozen at the original assessment. Historical financial series passed the financial fact-check gate against primary filings.